Vincent L Chen, Don C Rockey, Einar S Bjornsson, Huiman Barnhart, Jay H Hoofnagle
{"title":"处方药引起的偶发性药物性肝损伤的发生率。","authors":"Vincent L Chen, Don C Rockey, Einar S Bjornsson, Huiman Barnhart, Jay H Hoofnagle","doi":"10.1007/s40264-024-01486-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The incidence of drug-induced liver injury (DILI) is not known for most prescription medications. We aimed to estimate the incidence of DILI for commonly prescribed outpatient drugs.</p><p><strong>Methods: </strong>To establish a baseline estimate of DILI incidence, we used the estimated incidence (EI) of amoxicillin/clavulanate DILI from a previous population-based study in Iceland. This was combined with the multicenter prospective DILI Network (DILIN) cohort and the US population-based Medical Expenditure Panel Survey (MEPS). From 2005 to 2019, prescription drugs with at least five bona fide DILIN cases and data from at least 10 of the 15 years from MEPS during that timeframe were included. The EI for 'drug A' was calculated as follows: <math><mrow><mtext>EI</mtext> <mrow><mo>(</mo> <mtext>drug A</mtext> <mo>)</mo></mrow> <mo>=</mo> <mtext>EI</mtext> <mfenced><mtext>AC</mtext></mfenced> <mo>×</mo> <mfrac><mrow><mo>#</mo> <mspace></mspace> <mtext>DILIN cases of drug A</mtext></mrow> <mrow><mo>#</mo> <mspace></mspace> <mtext>annual new prescriptions of drug A</mtext></mrow> </mfrac> <mo>×</mo> <mfrac><mrow><mo>#</mo> <mspace></mspace> <mtext>annual new prescriptions of AC</mtext></mrow> <mrow><mo>#</mo> <mspace></mspace> <mtext>DILIN cases of AC</mtext></mrow> </mfrac> </mrow> </math> RESULTS: In total, 30 drugs met the inclusion criteria, of which 11 were antibiotics, 4 were antiepileptic drugs (AEDs), 4 were statins, and 11 were other drug types. The highest EI was seen with azathioprine and older AEDs, with one DILI case per 349-2329 new prescriptions. The EI of antibiotics ranged greatly, with the highest risk seen for minocycline, amoxicillin/clavulanate, and nitrofurantoin (approximately 1:1000-2400 new prescriptions), and lowest risk for clindamycin, doxycycline, azithromycin, and amoxicillin (approximately 1:40,000-170,000 new prescriptions). The EI for commonly prescribed statins was approximately 1:10,000-50,000. Important medication classes with > 5 million new prescriptions from 2005 to 2019 but fewer than five DILIN cases included β-blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, selective serotonin reuptake inhibitors, and metformin, which presumably have very low DILI incidence.</p><p><strong>Conclusions: </strong>The highest EI was found for azathioprine, older antiepileptics, and minocycline. In contrast, many widely used drugs are rare causes of DILI. These findings may help clinicians better weigh potential benefits of medications against hepatotoxicity risk.</p>","PeriodicalId":11382,"journal":{"name":"Drug Safety","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs.\",\"authors\":\"Vincent L Chen, Don C Rockey, Einar S Bjornsson, Huiman Barnhart, Jay H Hoofnagle\",\"doi\":\"10.1007/s40264-024-01486-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The incidence of drug-induced liver injury (DILI) is not known for most prescription medications. We aimed to estimate the incidence of DILI for commonly prescribed outpatient drugs.</p><p><strong>Methods: </strong>To establish a baseline estimate of DILI incidence, we used the estimated incidence (EI) of amoxicillin/clavulanate DILI from a previous population-based study in Iceland. This was combined with the multicenter prospective DILI Network (DILIN) cohort and the US population-based Medical Expenditure Panel Survey (MEPS). From 2005 to 2019, prescription drugs with at least five bona fide DILIN cases and data from at least 10 of the 15 years from MEPS during that timeframe were included. The EI for 'drug A' was calculated as follows: <math><mrow><mtext>EI</mtext> <mrow><mo>(</mo> <mtext>drug A</mtext> <mo>)</mo></mrow> <mo>=</mo> <mtext>EI</mtext> <mfenced><mtext>AC</mtext></mfenced> <mo>×</mo> <mfrac><mrow><mo>#</mo> <mspace></mspace> <mtext>DILIN cases of drug A</mtext></mrow> <mrow><mo>#</mo> <mspace></mspace> <mtext>annual new prescriptions of drug A</mtext></mrow> </mfrac> <mo>×</mo> <mfrac><mrow><mo>#</mo> <mspace></mspace> <mtext>annual new prescriptions of AC</mtext></mrow> <mrow><mo>#</mo> <mspace></mspace> <mtext>DILIN cases of AC</mtext></mrow> </mfrac> </mrow> </math> RESULTS: In total, 30 drugs met the inclusion criteria, of which 11 were antibiotics, 4 were antiepileptic drugs (AEDs), 4 were statins, and 11 were other drug types. The highest EI was seen with azathioprine and older AEDs, with one DILI case per 349-2329 new prescriptions. The EI of antibiotics ranged greatly, with the highest risk seen for minocycline, amoxicillin/clavulanate, and nitrofurantoin (approximately 1:1000-2400 new prescriptions), and lowest risk for clindamycin, doxycycline, azithromycin, and amoxicillin (approximately 1:40,000-170,000 new prescriptions). The EI for commonly prescribed statins was approximately 1:10,000-50,000. Important medication classes with > 5 million new prescriptions from 2005 to 2019 but fewer than five DILIN cases included β-blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, selective serotonin reuptake inhibitors, and metformin, which presumably have very low DILI incidence.</p><p><strong>Conclusions: </strong>The highest EI was found for azathioprine, older antiepileptics, and minocycline. In contrast, many widely used drugs are rare causes of DILI. These findings may help clinicians better weigh potential benefits of medications against hepatotoxicity risk.</p>\",\"PeriodicalId\":11382,\"journal\":{\"name\":\"Drug Safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40264-024-01486-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40264-024-01486-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:大多数处方药的药物性肝损伤(DILI)发生率尚不清楚。我们旨在估算门诊常用处方药的 DILI 发生率:为了确定 DILI 发生率的基线估计值,我们使用了之前在冰岛进行的一项基于人群的研究得出的阿莫西林/克拉维酸 DILI 估计发生率 (EI)。这与多中心前瞻性 DILI 网络 (DILIN) 队列和美国基于人口的医疗支出面板调查 (MEPS) 相结合。从 2005 年到 2019 年,至少有五例真正的 DILIN 病例的处方药以及该时间段内 MEPS 15 年中至少 10 年的数据都被纳入其中。药物 A "的 EI 计算如下:EI ( 药物 A ) = EI AC × # 药物 A 的 DILIN 病例数 # 药物 A 的年度新增处方数 × # AC 的年度新增处方数 # AC 的 DILIN 病例数 结果:共有 30 种药物符合纳入标准,其中 11 种为抗生素,4 种为抗癫痫药物 (AED),4 种为他汀类药物,11 种为其他类型药物。硫唑嘌呤和较老的 AEDs 的 EI 最高,每 349-2329 个新处方中就有一个 DILI 病例。抗生素的 EI 差别很大,米诺环素、阿莫西林/克拉维酸和硝基呋喃妥因的风险最高(约为新处方的 1:1000-2400 倍),而克林霉素、强力霉素、阿奇霉素和阿莫西林的风险最低(约为新处方的 1:40000-170000 倍)。常用他汀类药物的 EI 约为 1:10000-50000。从 2005 年到 2019 年,新处方超过 500 万张但 DILIN 病例少于 5 例的重要药物类别包括 β 受体阻滞剂、噻嗪类利尿剂、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、选择性血清素再摄取抑制剂和二甲双胍,这些药物的 DILI 发生率可能非常低:硫唑嘌呤、较老的抗癫痫药和米诺环素的 EI 最高。相比之下,许多广泛使用的药物很少导致 DILI。这些发现有助于临床医生更好地权衡药物的潜在益处与肝毒性风险。
Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs.
Background: The incidence of drug-induced liver injury (DILI) is not known for most prescription medications. We aimed to estimate the incidence of DILI for commonly prescribed outpatient drugs.
Methods: To establish a baseline estimate of DILI incidence, we used the estimated incidence (EI) of amoxicillin/clavulanate DILI from a previous population-based study in Iceland. This was combined with the multicenter prospective DILI Network (DILIN) cohort and the US population-based Medical Expenditure Panel Survey (MEPS). From 2005 to 2019, prescription drugs with at least five bona fide DILIN cases and data from at least 10 of the 15 years from MEPS during that timeframe were included. The EI for 'drug A' was calculated as follows: RESULTS: In total, 30 drugs met the inclusion criteria, of which 11 were antibiotics, 4 were antiepileptic drugs (AEDs), 4 were statins, and 11 were other drug types. The highest EI was seen with azathioprine and older AEDs, with one DILI case per 349-2329 new prescriptions. The EI of antibiotics ranged greatly, with the highest risk seen for minocycline, amoxicillin/clavulanate, and nitrofurantoin (approximately 1:1000-2400 new prescriptions), and lowest risk for clindamycin, doxycycline, azithromycin, and amoxicillin (approximately 1:40,000-170,000 new prescriptions). The EI for commonly prescribed statins was approximately 1:10,000-50,000. Important medication classes with > 5 million new prescriptions from 2005 to 2019 but fewer than five DILIN cases included β-blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, selective serotonin reuptake inhibitors, and metformin, which presumably have very low DILI incidence.
Conclusions: The highest EI was found for azathioprine, older antiepileptics, and minocycline. In contrast, many widely used drugs are rare causes of DILI. These findings may help clinicians better weigh potential benefits of medications against hepatotoxicity risk.
期刊介绍:
Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:
Overviews of contentious or emerging issues.
Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.
In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area.
Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
Editorials and commentaries on topical issues.
Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.